Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
Status:
Recruiting
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to see if using an investigational drug called [18F]FMISO with
PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on
chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is
for imaging purposes only and is not a treatment study. The results of this study will not
change a patient's clinical treatment plan but it may help physicians and researchers better
understand how best to treat patients with breast cancer in the future.